Favorable Long-Term Results With Ranibizumab Implant for Neovascular AMD
The ranibizumab port delivery system (PDS; Susvimo) with 6-month refill maintained noninferiority to monthly intravitreal injections for neovascular age-related macular degeneration (nAMD) out to 2 years, according to updated results from a randomized trial. Three assessments of best corrected visual acuity (BCVA) during years 1 to 2 showed differences ranging from -0.2 to +0.4 ETDRS […]
Long-Acting Injectable HIV Regimen on Par With Daily Drugs
SEATTLE — People living with HIV who have maintained undetectable virus levels with daily oral treatment could safely ditch the pills and transition to a more convenient every 2-month injectable alternative — without sacrificing efficacy, researchers found. In the 12-month results of the SOLAR trial, switching to the injectable long-acting cabotegravir plus rilpivirine (Cabenuva) from […]
10-Year Follow-Up Confirms Benefit of Chemoradiotherapy in MIBC Patients
Long-term results confirmed that the benefit of adding chemotherapy to radiotherapy was maintained in patients with muscle-invasive bladder cancer (MIBC) in a follow-up to the phase III randomized BC2001 trial. Over a median follow-up of about 10 years, locoregional control was significantly improved by adding 5-fluorouracil and mitomycin C to radiotherapy, with a 5-year recurrence-free […]